Jaguar Health Inc. (JAGX)
0.94
0.05 (5.62%)
At close: Jan 28, 2025, 1:58 PM
undefined% (undefined)
| Bid | 0.93 |
| Market Cap | 11.03M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 20.2 |
| PE Ratio (ttm) | 0.05 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.94 |
| Volume | 219,965 |
| Avg. Volume (20D) | 452,979 |
| Open | 0.92 |
| Previous Close | 0.89 |
| Day's Range | 0.87 - 0.94 |
| 52-Week Range | 0.78 - 21.60 |
| Beta | undefined |
About JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer fo...
Industry Biotechnology
Sector Healthcare
IPO Date May 12, 2015
Employees 49
Stock Exchange NASDAQ
Ticker Symbol JAGX
Website https://jaguar.health
Next Earnings Release
Jaguar Health Inc. is scheduled to release its earnings on Mar 31, 2025,
before market opens.
Analysts project revenue of $3.13M, reflecting a 36.09% YoY growth and earnings per share of -0.74, making a -276.19% decrease YoY.
Analysts project revenue of $3.13M, reflecting a 36.09% YoY growth and earnings per share of -0.74, making a -276.19% decrease YoY.
5 months ago
-10.83%
Jaguar Health shares are trading lower after the c...
Unlock content with
Pro Subscription
6 months ago
-58.78%
Jaguar Health is trading lower after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.
